

Dear Editor of the *World Journal of Experimental Medicine*

Thank you for your e-mail

We have addressed the reviewer's note regarding the submission (ID: 85135) and supplied a point-to-point response; hope it will meet your approval

Sincerely

Wassan Nori

Reviewer #1

Greetings, Author(s), Please correct the following errors: -

I hope the author(s) change the title to be more short and descriptive of why this "Letter to the Editor" was written.

Response Done

- Rewrite the conclusion on page 4 to show whether the research problem has been solved or not, or whether the current research has met its objectives.

Response

In conclusion, hydroxychloroquine has demonstrated efficacy in mitigating the activity of autoimmune diseases and some of their adverse pregnancy outcomes while maintaining a favorable safety profile. HCQ has emerged as a potential therapeutic option for cases with chronic placental inflammation, as it enhances live birth rates while decreasing the severity of the associated disease. Nevertheless, the efficacy and safety of HCQ in pregnant individuals with COVID-19 have not been thoroughly assessed. Further research is needed to unveil more applications in practice

- The number of references utilized exceeds what is required.

Please keep the references that support the topic of this "Letter to the Editor" concise.

Also, there are references that are not recent,

therefore I request author(s) to limit the usage of references until 2023 and five years after that. Good luck,

Response

done all references are up to date

still according to the journal guideline, the reference number has no limit and we have added the most recent ones to improve the impact of the letter. kindly check <https://www.wjgnet.com/bpg/GerInfo/219>

Reviewer #2

Thank you for your positive feedback we appreciate it .

Reviewer #3

1.The structure of this article isdispersible and can be explained more profoundly.The hierarchy of the article is not clear enough.

Response

Hydroquinone had an update regarding its use among pregnant; first in autoimmune diseases and its safety profile. Second its therapeutic role in cases with chronic placental inflammation. Finally we discuss its potential use in pregnant with COVID-19 which is worth mentioning and was not discussed by Bajpai et al.'s study.

2.I suggest that the format of the references needs to be revised.

Response

Done

3. Are there any differences in hydroxychloroquine use in Pregnancy between the COVID-19 pandemic and non-COVID-19pandemi

Response This part was explained more; see

Nevertheless, the efficacy and safety of HCQ in pregnant individuals with COVID-19 have not been thoroughly assessed. Further research is needed to unveil more applications in practice.